New treatment targets natural tears for dry eyes

RESTASIS®1 is Now Approved by Health Canada for the Treatment of Dry Eye Disease

TORONTO, Nov. 25 /PRNewswire/ - To view this Social Media Release, please enter the following address in your web browser.

http://smr.newswire.ca/en/allergan-inc/new-treatment-targets-natural-tears-for-dry-eyes

/NOTE TO PHOTO EDITORS: Photos accompanying this release are also available at http://photos.newswire.ca. Images are free to accredited members of the media/

SOURCE Allergan Inc.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.